Clinical trials: Pulmonary Hypertension
Pulmonary Arterial Hypertension
Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
This is a 12-week, international, multicenter, double-blind, three-group, dose-response study to assess the safety and efficacy of BPS-MR in patients with PAH.
- Trial name
- NCT00989963
- Testing
- Beraprost Sodium Modified Release
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 36 people
- Sponsor
- Lung Biotechnology PBC
Pulmonary Arterial Hypertension
Bosentan and Pulmonary Endothelial Function
6 months therapy of Bosentan, an endothelin antagonist, will lead to improvement in pulmonary microvascular endothelial function.
- Trial name
- PARBO (NCT01721564)
- Testing
- Bosentan
- Volunteers
- 8 people
- Sponsor
- Prof David S Celermajer
Pulmonary Hypertension
BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521.
- Trial name
- CHEST-2 (NCT00910429)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 73 sites in United States, Argentina and 24 more
- Volunteers
- 237 people
- Sponsor
- Bayer
Sickle Cell Disease, Pulmonary Hypertension
Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension
The goal of this study is to test the hypothesis that hydroxyurea is effective for the specific treatment of secondary pulmonary hypertension found on screening in children and young adults with sickle cell disease.
- Trial name
- NCT00350844
- Testing
- Hydroxyurea
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Pulmonary Hypertension
Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide
Acute secondary pulmonary hypertension (PH) often leads to dysfunction of the right ventricle (RV) and can be a significant cause of patient morbidity and mortality.
- Trial name
- NCT02170519
- Testing
- Inhaled Iloprost
- Volunteers
- 27 people
- Sponsor
- Duke University
Chronic Thromboembolic Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).
- Trial name
- MACiTEPH (NCT04271475)
- Testing
- Macitentan
- Where
- 168 sites in United States, Argentina and 31 more
- Volunteers
- 127 people
- Sponsor
- Actelion
Stress, Psychological
OUR Stress/ Emotion Management for Black/African American Women With Hypertension
Covid-19 is an additional stressor Black women have to deal with that may interfere with hypertension self-care management. Social connectedness is a source of resilience for Black women to promote mental and physical health.
- Trial name
- OUR-Project (NCT04526145)
- Testing
- Stress and emotion management
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Pulmonary Hypertension
Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease
Sickle cell disease (SCD) is often referred to as a hypercoagulable state. However, the contribution of coagulation activation to the pathogenesis of SCD remains uncertain.
- Trial name
- NCT01036802
- Testing
- Warfarin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of North Carolina, Chapel Hill
Pulmonary Hypertension Associated With HFpEF
Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF
This was an open-label study to evaluate the safety of continued therapy with oral treprostinil in subjects who completed Study TDE-HF-301.
- Trial name
- NCT03043651
- Testing
- Oral treprostinil
- Where
- 82 sites in United States
- Volunteers
- 48 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients
This is an open-label extension study for patients who participated in the BPS-MR-PAH-201 study.
- Trial name
- NCT00792571
- Testing
- Beraprost Sodium Modified Release
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 18 people
- Sponsor
- Lung Biotechnology PBC
Aortic Stenosis
Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study
Currently, aortic stenosis (AS) is considered a "surgical disease" with no medical therapy available to improve any clinical outcomes, including symptoms, time to surgery, or long-term survival.
- Trial name
- ASPEN-AVR (NCT01272388)
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Pulmonary Arterial Hypertension
A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)
This study of frespaciguat in participants with Group 1 pulmonary arterial hypertension (PAH) will assess the safety, tolerability and pharmacokinetics (PK) of inhaled frespaciguat. There is no formal hypothesis to be tested.
- Trial name
- NCT03744637
- Testing
- Frespaciguat
- Where
- Moldova
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Hypertension
Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
STUDY OBJECTIVES Primary objective To evaluate the effect of macitentan 10 mg on pulmonary vascular resistance (PVR) as compared to placebo in subjects with pulmonary hypertension (PH) after left ventricular assist device (LVAD)…
- Trial name
- SOPRANO (NCT02554903)
- Testing
- Macitentan 10mg
- Where
- 50 sites in United States
- Volunteers
- 57 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
This study is an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have completed the TDE-PH-310 study.
- Trial name
- NCT01560637
- Testing
- UT-15C (treprostinil diolamine)
- Where
- 153 sites in United States, Argentina and 21 more
- Volunteers
- 471 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Iloprost Power Disc-15 in Pulmonary Arterial Hypertension
A Phase IIIb, Multicenter, Open-Label Study of Patients With Pulmonary Arterial Hypertension Treated With Iloprost(Inhalation)Evaluating Safety and Inhalation Times When Converting From Power Disc-6 to Power Disc-15 With the…
- Trial name
- INHALE-15 (NCT00723554)
- Testing
- Iloprost PD-6, Iloprost PD-15
- Where
- 36 sites in United States
- Volunteers
- 63 people
- Sponsor
- Actelion
Prematurity, Respiratory Insufficiency
Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)
This is a randomized controlled trial (RCT) on the use of Inhaled prostaglandin E1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure (NHRF).
- Conditions
- Prematurity, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn
- Trial name
- NCT01467076
- Testing
- Aerosolized Normal Saline, Inhaled PGE1
- Where
- 11 sites in United States
- Volunteers
- 7 people
- Sponsor
- NICHD Neonatal Research Network
Chronic Thromboembolic Pulmonary Hypertension
The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension
Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery.Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling.
- Trial name
- NCT04773028
- Testing
- matrix metalloproteinase enzymes 2 and 9
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- AHMET ZENGIN
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Comparative Effectiveness of Telemedicine in Primary Care
Leveraging a natural experiment approach, the investigators will examine rapidly changing telemedicine and in-person models of care during and after the COVID-19 crisis to determine whether certain patients could safely choose to…
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure, Diabetes
- Trial name
- NCT04684836
- Testing
- Exposure to telemedicine, after the onset of the pandemic
- Where
- 4 sites in United States
- Volunteers
- 33,100 people
- Sponsor
- Weill Medical College of Cornell University
Pulmonary Arterial Hypertension, Systemic Sclerosis
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease…
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease
- Trial name
- ATPAHSS (NCT01042158)
- Testing
- tadalafil and ambrisentan upfront combination therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University